Natriuretic Peptide, Brain

"Natriuretic Peptide, Brain" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A PEPTIDE that is secreted by the BRAIN and the HEART ATRIA, stored mainly in cardiac ventricular MYOCARDIUM. It can cause NATRIURESIS; DIURESIS; VASODILATION; and inhibits secretion of RENIN and ALDOSTERONE. It improves heart function. It contains 32 AMINO ACIDS.

Descriptor ID	D020097
MeSH Number(s)	D06.472.699.584.625 D12.644.548.585.625 D12.776.631.590
Concept/Terms	Natriuretic Peptide, Brain Natriuretic Peptide, Brain Peptide, Brain Natriuretic BNP-32 BNP 32 Brain Natriuretic Peptide-32 Brain Natriuretic Peptide 32 Natriuretic Peptide-32, Brain Peptide-32, Brain Natriuretic Natriuretic Factor-32 Natriuretic Factor 32 BNP Gene Product Type-B Natriuretic Peptide Natriuretic Peptide, Type-B Type B Natriuretic Peptide Natriuretic Peptide Type-B Natriuretic Peptide Type B Nesiritide Brain Natriuretic Peptide B-Type Natriuretic Peptide Natriuretic Peptide, B-Type Ventricular Natriuretic Peptide, B-type Ventricular Natriuretic Peptide, B-type Ventricular Natriuretic Peptide, B type Natrecor Natrecor

Below are MeSH descriptors whose meaning is more general than "Natriuretic Peptide, Brain".

Chemicals and Drugs [D]
Hormones, Hormone Substitutes, and Hormone Antagonists [D06]
Hormones [D06.472]
Peptide Hormones [D06.472.699]
Natriuretic Peptides [D06.472.699.584]
Natriuretic Peptide, Brain [D06.472.699.584.625]
Amino Acids, Peptides, and Proteins [D12]
Peptides [D12.644]
Peptide Hormones [D12.644.548]
Natriuretic Peptides [D12.644.548.585]
Natriuretic Peptide, Brain [D12.644.548.585.625]
Proteins [D12.776]
Nerve Tissue Proteins [D12.776.631]
Natriuretic Peptide, Brain [D12.776.631.590]

Below are MeSH descriptors whose meaning is related to "Natriuretic Peptide, Brain".

Below are MeSH descriptors whose meaning is more specific than "Natriuretic Peptide, Brain".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Natriuretic Peptide, Brain" by people in this website by year, and whether "Natriuretic Peptide, Brain" was a major or minor topic of these publications.

Bar chart showing 37 publications over 17 distinct years, with a maximum of 4 publications in 2022 and 2025

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2003	2	1	3
2004	3	0	3
2005	0	1	1
2006	1	0	1
2013	2	0	2
2014	1	0	1
2015	2	0	2
2016	0	2	2
2018	1	1	2
2019	2	0	2
2020	1	1	2
2021	1	2	3
2022	1	3	4
2023	0	1	1
2024	1	1	2
2025	1	3	4
2026	0	2	2

Below are the most recent publications written about "Natriuretic Peptide, Brain" by people in Profiles.

Kramer CM, Kolm P, DiMarco JP, Desai MY, Ho CY, Kwong RY, Dolman SF, Desvigne-Nickens P, Geller N, Kim DY, Schulz-Menger J, Friedrich MG, Maron MS, Appelbaum E, Link MS, Francis GS, Greenberg B, Jerosch-Herold M, Piechnik S, Mahmod M, Raman B, Jacoby DL, Baldassare LA, White JA, Chiribiri A, Helms AS, Choudhury L, Michels M, Bradlow WM, Salerno M, Heitner SB, Masri A, Prasad SK, Mohiddin SA, Plein S, Madias C, Mahrholdt H, Bucciarelli-Ducci C, Nightingale AK, Weinsaft JW, Kim HW, McCann GP, van Rossum A, Germans T, Williamson EE, Geske JB, Flett AS, Dawson D, Mongeon FP, Olivotto I, Crean AM, Woo A, Owens AT, Anderson L, Sharma S, Biagini E, Newby DE, Andre F, Berry C, Kim B, Larose E, Abraham TP, Hays AG, Sherrid MV, Gelfand EV, Nagueh SF, Rimoldi O, Camici P, Elstein E, Autore C, Watkins H, Weintraub WS, Neubauer S. Predictors of Long-Term Outcomes in Hypertrophic Cardiomyopathy: The NHLBI HCM Registry. JAMA. 2026 Jun 09; 335(22):1959-1969.

View in: PubMed
Veselka J, Gimeno R, Abraham TP, Barriales-Villa R, Claggett BL, Coats CJ, Hegde SM, Januzzi JL, Masri A, Miao ZM, Nassif ME, Olivotto I, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Wohltman A, Maron MS. Efficacy of Aficamten in Hypertrophic Cardiomyopathy Patients With Very-High Left Ventricular Outflow Tract Gradients. Am J Cardiol. 2026 Jul 01; 270:133-141.

View in: PubMed
Wang X, Pabon MA, Makuvire TT, Maimaiti R, Abraham TP, Barriales-Villa R, Claggett BL, Coats CJ, Maron MS, Masri A, Meder B, Nassif ME, Olivotto I, Owens AT, Saberi S, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Wohltman A, Solomon SD, Hegde SM. Effect of Aficamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy in SEQUOIA-HCM. Circ Heart Fail. 2026 Jan; 19(1):e013918.

View in: PubMed
Garcia-Pavia P, Maron MS, Masri A, Merkely B, Nassif ME, Pe?a-Pe?a ML, Barriales-Villa R, Bilen O, Burroughs M, Claggett B, Costabel JP, Correia EB, Dybro AM, Elliott P, Hegde SM, Lakdawala NK, Lewis GD, Mann A, Miao ZM, Nair A, Poulsen SH, Reant P, Schulze PC, Solomon SD, Wang A, Sohn R, Berhane I, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Wohltman A, Fifer MA. Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy. N Engl J Med. 2025 Sep 11; 393(10):949-960.

View in: PubMed
Kovell LC, Denu MKI, Berkowitz J, Shankara S, Shao C, Skaritanov E, Wilkie G, Simas TAM, Juraschek SP. Cardiac Biomarkers in Pregnancies With and Without Hypertension. Am J Hypertens. 2025 08 14; 38(9):697-705.

View in: PubMed
Maron MS, Gimeno JR, Veselka J, Barriales-Villa R, Claggett BL, Coats CJ, Hegde SM, Januzzi JL, Kulac IJ, Masri A, Nassif ME, Spertus JA, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Wohltman A, Olivotto I. Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trial. Eur Heart J. 2025 10 22; 46(40):4076-4086.

View in: PubMed
Coats CJ, Masri A, Barriales-Villa R, Abraham TP, Brinkley DM, Claggett BL, Hagege A, Hegde SM, Ho CY, Kulac IJ, Lee MMY, Maron MS, Olivotto I, Owens AT, Solomon SD, Tfelt-Hansen J, Watkins H, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, Januzzi JL. Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trial. Eur Heart J. 2024 Nov 08; 45(42):4464-4478.

View in: PubMed
Masri A, Sherrid MV, Abraham TP, Choudhury L, Garcia-Pavia P, Kramer CM, Barriales-Villa R, Owens AT, Rader F, Nagueh SF, Olivotto I, Saberi S, Tower-Rader A, Wong TC, Coats CJ, Watkins H, Fifer MA, Solomon SD, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Meng L, Sohn RL, Wohltman A, Maron MS. Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4. J Card Fail. 2024 11; 30(11):1439-1448.

View in: PubMed
Belanger MJ, Kovell LC, Turkson-Ocran RA, Mukamal KJ, Liu X, Appel LJ, Miller ER, Sacks FM, Christenson RH, Rebuck H, Chang AR, Juraschek SP. Effects of the Dietary Approaches to Stop Hypertension Diet on Change in Cardiac Biomarkers Over Time: Results From the DASH-Sodium Trial. J Am Heart Assoc. 2023 01 17; 12(2):e026684.

View in: PubMed
Barbhuiya MA, Neibauer T, Saylor E, Zhu Y. Comparison of Performance between the Elecsys 4th and 5th Generation STAT Cardiac Troponin T Immunoassays. Ann Clin Lab Sci. 2022 Jul; 52(4):628-633.

View in: PubMed

People

Explore

Similar Concepts

Top Journals